Molecular and Genetic Studies of Congenital Myopathies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00272883|
Recruitment Status : Recruiting
First Posted : January 9, 2006
Last Update Posted : December 9, 2016
|Condition or disease|
|Central Core Disease Centronuclear Myopathy Congenital Fiber Type Disproportion Multiminicore Disease Myotubular Myopathy Nemaline Myopathy Rigid Spine Muscular Dystrophy Undefined Congenital Myopathy|
The Congenital Myopathy Research Program consists of a group of scientists and healthcare providers all working to better understand the congenital myopathies. We are taking two approaches to reach our research goals. The first involves identifying and describing new genes and proteins involved in the skeletal muscles that allow our bodies to move. Simultaneously, studies are underway to identify genetic changes (mutations) that cause human neuromuscular disease. Thus, our second approach is to identify mutations, learn how they are inherited in families, and understand how they lead to weakness in individuals with neuromuscular disease. These approaches allow correlation of our basic muscle biology findings with our studies on muscle tissue of affected individuals.
Our research would not be possible without the generous participation of individuals and families with congenital myopathies. Participation in our studies is free of charge. Travel to Boston is not required, and we welcome the participation of individuals from around the world.
We appreciate the participation of all individuals with a congenital myopathy, as well as their first-degree relatives. Participants with a congenital myopathy are asked to donate medical records, a blood or saliva sample, and a muscle tissue sample (if available). Participating relatives are asked to donate a blood sample. The blood/saliva sample is used to acquire DNA (genetic material) which can be used to identify genetic changes and to study how a disease is inherited in a family. The medical records are employed to understand a participant's symptoms. The muscle tissue is used to better understand the disease at the muscular level by studying the gene expression and protein levels in individuals with congenital myopathies.
For more information, visit the Laboratory Website at www.childrenshospital.org/research/beggs.
|Study Type :||Observational|
|Estimated Enrollment :||4000 participants|
|Official Title:||Molecular Analysis of Neuromuscular Disease|
|Study Start Date :||August 2003|
|Estimated Primary Completion Date :||January 2050|
|Estimated Study Completion Date :||January 2050|
- Identification of Neuromuscular Disease Genes [ Time Frame: The time frame for disease gene discovery is unpredictable and may range from several days to several decades. ]This is an ongoing genetic discovery study aimed at finding and confirming pathogenic mutations in known and new disease genes.
- Characterization of Clinical Features of Congenital Myopathies [ Time Frame: The time frame for disease classifacation and genotype-phenotype correlation is unpredictable and may range from several days to several decades. ]As known as known and new disease genes are identified the resulting genotypes are correlated with subject phenotypes.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00272883
|Contact: Casie Genetti, M.S. C.G.C.||(617) email@example.com|
|Contact: Beggs firstname.lastname@example.org|
|United States, Massachusetts|
|Genetics Division, Boston Children's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Casie Genetti, M.S. C.G.C. 617-919-2169 email@example.com|
|Principal Investigator: Alan H. Beggs, Ph.D.|
|Principal Investigator:||Alan H. Beggs, Ph.D.||Children's Hospital Boston/Harvard Medical School|